NASDAQ:SPHS - Sophiris Bio News Headlines

Sign in or create an account to add this stock to your watchlist.
$1.08 -0.04 (-3.57 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.08
Today's Range$1.02 - $1.1480
52-Week Range$0.75 - $4.05
Volume241,488 shs
Average Volume143,754 shs
Market Capitalization$32.64 million
P/E Ratio-2.08
Dividend YieldN/A
Beta2.94

Headlines

Sophiris Bio (NASDAQ SPHS) News Headlines

Source:
DateHeadline
 Brokerages Expect Sophiris Bio Inc (SPHS) to Announce -$0.08 EPS Brokerages Expect Sophiris Bio Inc (SPHS) to Announce -$0.08 EPS
www.americanbankingnews.com - March 19 at 8:28 PM
Sophiris Bio Inc (SPHS) Forecasted to Post Q1 2019 Earnings of ($0.05) Per ShareSophiris Bio Inc (SPHS) Forecasted to Post Q1 2019 Earnings of ($0.05) Per Share
www.americanbankingnews.com - March 18 at 1:13 AM
Sophiris Bio Inc (SPHS) Expected to Earn Q1 2020 Earnings of ($0.17) Per ShareSophiris Bio Inc (SPHS) Expected to Earn Q1 2020 Earnings of ($0.17) Per Share
www.americanbankingnews.com - March 15 at 8:19 AM
Sophiris Bio (SPHS) PT Lowered to $3.50Sophiris Bio (SPHS) PT Lowered to $3.50
www.americanbankingnews.com - March 14 at 12:37 PM
Sophiris Bio (SPHS) Given New $5.00 Price Target at Piper Jaffray CompaniesSophiris Bio (SPHS) Given New $5.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - March 13 at 9:35 PM
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate HighlightsSophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 13 at 5:54 PM
Sophiris Bio Phase 2b Results Crushed On Data, But Is Still Pressing OnSophiris Bio Phase 2b Results Crushed On Data, But Is Still Pressing On
seekingalpha.com - December 20 at 9:32 AM
SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…
finance.yahoo.com - December 19 at 9:34 AM
Sophiris Bio Shares Dive 27% as Study Results Show No Additional Benefit of Second Treatment of TopsalysinSophiris Bio Shares Dive 27% as Study Results Show No Additional Benefit of Second Treatment of Topsalysin
www.nasdaq.com - December 17 at 4:45 PM
Sophiris Bio down 38% on disappointing topsalysin dataSophiris Bio down 38% on disappointing topsalysin data
seekingalpha.com - December 17 at 4:45 PM
Sophiris Bio (SPHS) Says Additional Benefit was not Observed on Targeted biopsy Six months After re-treatment with Second Administration of TopsalysinSophiris Bio (SPHS) Says Additional Benefit was not Observed on Targeted biopsy Six months After re-treatment with Second Administration of Topsalysin
www.streetinsider.com - December 17 at 4:45 PM
Healthcare stocks among premarket losersHealthcare stocks among premarket losers
seekingalpha.com - December 17 at 9:28 AM
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer TrialSophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
www.prnewswire.com - December 17 at 8:11 AM
Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
finance.yahoo.com - December 6 at 9:20 AM
SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…
finance.yahoo.com - November 20 at 4:34 PM
Sophiris Bio to Present at the Piper Jaffray Healthcare ConferenceSophiris Bio to Present at the Piper Jaffray Healthcare Conference
finance.yahoo.com - November 15 at 4:28 PM
Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsSophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
finance.yahoo.com - November 13 at 4:31 PM
Sophiris Bio to Present at the Cantor Global Healthcare ConferenceSophiris Bio to Present at the Cantor Global Healthcare Conference
finance.yahoo.com - September 25 at 9:21 AM
Sophiris Bio Extends the Interest Only Period under its Loan and Security AgreementSophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
finance.yahoo.com - September 14 at 9:30 AM
Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment ConferenceSophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
www.bizjournals.com - August 30 at 4:23 PM
Sophiris Bio (SPHS) says previously reported death of patient in its Phase 2b trial unlikely to be related to topsalysin or procedureSophiris Bio (SPHS) says previously reported death of patient in its Phase 2b trial unlikely to be related to topsalysin or procedure
www.streetinsider.com - August 30 at 4:23 PM
SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…
finance.yahoo.com - August 30 at 4:23 PM
Stock Move: Sophiris Bio Surges 30% on Determination Patient Death Unlikely Due to Prostate Cancer TreatmentStock Move: Sophiris Bio Surges 30% on Determination Patient Death Unlikely Due to Prostate Cancer Treatment
www.nasdaq.com - August 29 at 4:16 PM
Sophiris Bio up 8% premarket on resolution of patient death investigation in mid-stage topsalysin studySophiris Bio up 8% premarket on resolution of patient death investigation in mid-stage topsalysin study
seekingalpha.com - August 29 at 4:16 PM
Sophiris Bio Updates on Phase 2b Localized Prostate Cancer TrialSophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
finance.yahoo.com - August 29 at 9:44 AM
SPHS: Ready to Advance Topsalysin into Registration Studies…SPHS: Ready to Advance Topsalysin into Registration Studies…
finance.yahoo.com - August 21 at 4:20 PM
Sophiris Bio ends Q2 with $18.5M in quick assetsSophiris Bio ends Q2 with $18.5M in quick assets
seekingalpha.com - August 15 at 9:35 AM
Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate HighlightsSophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 14 at 4:22 PM
SPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate CancerSPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate Cancer
finance.yahoo.com - July 12 at 4:14 PM
Sophiris Bio Tumbles On Phase 2B Safety Issue, But Its Highly OverblownSophiris Bio Tumbles On Phase 2B Safety Issue, But It's Highly Overblown
seekingalpha.com - June 26 at 11:10 AM
Sophiris Bio Plunges 45% - Says 1st Dosing of Topsalysin Positive But A Patient Died After 2nd Dosing, Co Halts Dosing to Probe DeathSophiris Bio Plunges 45% - Says 1st Dosing of Topsalysin Positive But A Patient Died After 2nd Dosing, Co Halts Dosing to Probe Death
www.nasdaq.com - June 25 at 11:09 AM
Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate CancerSophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer
finance.yahoo.com - June 25 at 11:09 AM
Sophiris Bio shares plummet 46% on news of patient death in trial for prostate cancer drugSophiris Bio shares plummet 46% on news of patient death in trial for prostate cancer drug
finance.yahoo.com - June 25 at 11:09 AM
Sophiris: Upcoming Release For Top Line Data In Phase 2b Prostate CancerSophiris: Upcoming Release For Top Line Data In Phase 2b Prostate Cancer
seekingalpha.com - June 13 at 9:16 AM
Want To Invest In Sophiris Bio Inc (NASDAQ:SPHS)? Here’s How It Performed LatelyWant To Invest In Sophiris Bio Inc (NASDAQ:SPHS)? Here’s How It Performed Lately
finance.yahoo.com - June 11 at 9:14 AM
Piper Jaffray Assumes Sophiris Bio (SPHS) at OverweightPiper Jaffray Assumes Sophiris Bio (SPHS) at Overweight
www.streetinsider.com - May 29 at 4:27 PM
SPHS: Countdown to Release of Topline Data for Phase 2b Study of Topsalysin in Prostate Cancer at end of 2Q18SPHS: Countdown to Release of Topline Data for Phase 2b Study of Topsalysin in Prostate Cancer at end of 2Q18
finance.yahoo.com - May 21 at 4:26 PM
SPHS May 2018 2.500 callSPHS May 2018 2.500 call
finance.yahoo.com - May 18 at 10:23 AM
Sophiris Bio beats by $0.02Sophiris Bio beats by $0.02
seekingalpha.com - May 15 at 10:00 AM
Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate HighlightsSophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights
finance.yahoo.com - May 14 at 4:29 PM
Why Im Bullish On Sophiris Bios Upcoming Phase 2b Data ReleaseWhy I'm Bullish On Sophiris Bio's Upcoming Phase 2b Data Release
seekingalpha.com - May 7 at 4:36 PM
Loss-Making Sophiris Bio Inc (NASDAQ:SPHS) Expected To BreakevenLoss-Making Sophiris Bio Inc (NASDAQ:SPHS) Expected To Breakeven
finance.yahoo.com - May 6 at 9:41 AM
Sophiris Bio (SPHS) Presents At Needham and Company 17th Annual Healthcare Conference - SlideshowSophiris Bio (SPHS) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:26 PM
SPHS: Topline Results from Phase 2b Study of Topsalysin at end of 2Q18SPHS: Topline Results from Phase 2b Study of Topsalysin at end of 2Q18
finance.yahoo.com - March 26 at 4:18 PM
Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial ... - PR Newswire (press release)Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 4:23 PM
Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate HighlightsSophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights
finance.yahoo.com - March 21 at 4:23 PM
Sophiris Bio to Present at 17th Annual Needham Healthcare ConferenceSophiris Bio to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 15 at 4:55 PM
Sophiris Bio to Participate in the 10th Annual Biotech Showcase ConferenceSophiris Bio to Participate in the 10th Annual Biotech Showcase Conference
finance.yahoo.com - December 27 at 9:12 AM
Sophiris Bio (SPHS) Reports Complete Enrollment in Phase 2b ... - StreetInsider.comSophiris Bio (SPHS) Reports Complete Enrollment in Phase 2b ... - StreetInsider.com
www.streetinsider.com - December 12 at 6:58 AM
Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate CancerSophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer
finance.yahoo.com - December 11 at 3:20 PM
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel